Bank of America Upgrades Roche (OTCMKTS:RHHBY) to “Buy”

Roche (OTCMKTS:RHHBY) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a research note issued on Friday, Marketbeat.com reports.

Other equities research analysts have also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. The Goldman Sachs Group started coverage on shares of Roche in a research note on Thursday, May 30th. They set a “sell” rating on the stock. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold”.

Roche Price Performance

OTCMKTS:RHHBY opened at $39.11 on Friday. Roche has a twelve month low of $29.20 and a twelve month high of $42.43. The firm has a 50-day moving average price of $39.59 and a two-hundred day moving average price of $34.84. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.04 and a current ratio of 1.35.

Institutional Investors Weigh In On Roche

Several hedge funds have recently modified their holdings of the stock. Saratoga Research & Investment Management boosted its position in shares of Roche by 6.9% in the first quarter. Saratoga Research & Investment Management now owns 2,458,918 shares of the company’s stock worth $78,489,000 after acquiring an additional 158,482 shares during the last quarter. Cardinal Capital Management Inc. acquired a new stake in shares of Roche in the second quarter worth approximately $16,860,000. OLD National Bancorp IN raised its holdings in Roche by 3.2% in the second quarter. OLD National Bancorp IN now owns 265,242 shares of the company’s stock valued at $9,206,000 after buying an additional 8,146 shares during the period. Altrius Capital Management Inc raised its holdings in Roche by 6.0% in the second quarter. Altrius Capital Management Inc now owns 224,804 shares of the company’s stock valued at $7,794,000 after buying an additional 12,646 shares during the period. Finally, Meritage Portfolio Management raised its holdings in Roche by 186.9% in the first quarter. Meritage Portfolio Management now owns 174,714 shares of the company’s stock valued at $5,577,000 after buying an additional 113,823 shares during the period.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.